Clinical Trials Browser

Not yet recruiting × OTHER_GOV × Carcinoma, Non-Small-Cell Lung × Clear all

Carcinoma, Non-Small-Cell Lung

NCT06971406 2025-05-14

FLAME-1

Phase 2 Not yet recruiting

100 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06854939 2025-03-03

MRDSEEKER

Not yet recruiting

350 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT06786208 2025-01-22

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Not yet recruiting

55 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06760676 2025-01-07

A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

Phase 1 Not yet recruiting

90 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms

NCT06679712 2024-11-07

5ALA-TBPDT

Phase NA Not yet recruiting

6 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06618391 2024-10-01

Local Injection and Systemic Therapy in the Treatment of NSCLC.

Phase 2 Not yet recruiting

84 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06454890 2024-06-12

Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

NSCLC SCLC

FLAME-1

MRDSEEKER

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

5ALA-TBPDT

Local Injection and Systemic Therapy in the Treatment of NSCLC.

Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)